High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial

In contrast to resource-rich countries, most HIV-infected patients in resource-limited countries receive treatment without virological monitoring. There are few long-term data, in this setting, on rates of viral suppression or switch to second-line antiretroviral therapy. The DART trial compared cli...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Kityo, C, Gibb, D, Gilks, C, Goodall, R, Mambule, I, Kaleebu, P, Pillay, D, Kasirye, R, Mugyenyi, P, Walker, A, Dunn, D
Format:	Journal article
Język:	English
Wydane:	Public Library of Science 2014

Podobne zapisy

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
od: Cissy Kityo, i wsp.
Wydane: (2014-01-01)

DART and laboratory monitoring of HIV treatment Reply
od: Walker, A, i wsp.
Wydane: (2010)

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
od: Gilks, C, i wsp.
Wydane: (2012)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
od: Gomo, Z, i wsp.
Wydane: (2014)

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
od: Mugyenyi, P, i wsp.
Wydane: (2010)

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
od: Ndembi, N, i wsp.
Wydane: (2010)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
od: Walker, A, i wsp.
Wydane: (2010)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
od: Gilks, C, i wsp.
Wydane: (2013)

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
od: Stöhr, W, i wsp.
Wydane: (2011)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
od: Ssali, F, i wsp.
Wydane: (2006)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial
od: Parikh, S, i wsp.
Wydane: (2013)

Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
od: Muyingo, S, i wsp.
Wydane: (2008)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
od: Walker, A, i wsp.
Wydane: (2012)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
od: Reid, A, i wsp.
Wydane: (2008)

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
od: Ford, D, i wsp.
Wydane: (2015)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
od: Lara, A, i wsp.
Wydane: (2012)

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models
od: Ford, D, i wsp.
Wydane: (2015)

The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.
od: Kiwuwa-Muyingo, S, i wsp.
Wydane: (2012)

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
od: Munderi, P, i wsp.
Wydane: (2011)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.
od: Sujal M Parikh, i wsp.
Wydane: (2013-01-01)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
od: Munderi, P, i wsp.
Wydane: (2010)

Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.
od: McCormick, A, i wsp.
Wydane: (2010)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
od: Gibb, D, i wsp.
Wydane: (2012)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
od: Paton, N, i wsp.
Wydane: (2014)

CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.
od: Serwanga, J, i wsp.
Wydane: (2011)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
od: Hakim, J, i wsp.
Wydane: (2017)

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
od: Antonieta Medina Lara, i wsp.
Wydane: (2012-01-01)

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
od: Kasirye, P, i wsp.
Wydane: (2012)

Monitoring of highly active antiretroviral therapy in HIV infection.
od: Walker, A, i wsp.
Wydane: (2011)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
od: Ross, LL, i wsp.
Wydane: (2019)

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
od: Gibb, D, i wsp.
Wydane: (2002)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa
od: Paton, N, i wsp.
Wydane: (2014)

Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
od: Gibb, D, i wsp.
Wydane: (2004)

Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects
od: Haberer, J, i wsp.
Wydane: (2011)

Dynamics of emergence and linkage of HIV reverse transcriptase Q151M MDR complex in children within first-line antiretroviral rollout uncovered by single-genome sequencing
od: Mbisa, J, i wsp.
Wydane: (2009)

CD8+ T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4+ T Cells <200 Cell/μL: The DART Trial STI Substudy
od: Jennifer Serwanga, i wsp.
Wydane: (2011-01-01)

Professor Raymond Dart
od: J. D. Verster
Wydane: (1961-06-01)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
od: Bwakura-Dangarembizi, M, i wsp.
Wydane: (2015)

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
od: Stöhr, W, i wsp.
Wydane: (2013)

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
od: Kityo, C, i wsp.
Wydane: (2010)